



Journal Articles published in 2010

- Aasly JO, Vilarino-Guell C, Dachsel JC, Webber PJ, West AB, Haugarvoll K, Johansen KK, Toft M, **Nutt JG**, Payami H, Kachergus JM, Lincoln SJ, Felic A, Wilder C, Soto-Ortolaza AI, Cobb SA, White LR, Ross OA, Farrer MJ. Novel pathogenic LRRK2 p.Asn1437 His substitution in familial Parkinson's disease. *Movement Disorders*, 2010 Oct; 25(13): 2156-2163.
- Aranday Cortes E, Kaveh D, Nunez-Garcia J, **Hogarth PJ**, Vordermeier HM. Mycobacterium bovis-BCG vaccination induces specific pulmonary transcriptome biosignatures in mice. *PLoS One*, 2010 Jun; 5(6): e11319.
- Bekris, LM, Mata IF, **Zabetian CP**. The genetics of Parkinson Disease. *Journal of Geriatric Psychiatry and Neurology*, 2010 Dec; 23(4): 228-242.
- Brodsky MA**, Nutt JG. Parkinson disease: deep brain stimulation versus best medical therapy for PD. *Nat Rev Neurol*, 2010 Oct; 6(10): 530-532.
- Chung KA, Lobb BM, Nutt JG**, Horak FB. Effects of central cholinesterase inhibitor on reducing falls in Parkinson's disease. *Neurology*, 2010, Oct 5; 75(14): 1263-1269.
- Chung KA, Lobb BM, Nutt JG**, McNames J, Horak F. Objective measurement of dyskinesia in Parkinson's disease using a force plate. *Mov Disord*. 2010 Apr 15;25(5):602-8.
- Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM, **Quinn JF**, D'Angelo G, Malone JP, Townsend RR, Morris JC, Fagan AM, Hotzman DM. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. *Biological Psychiatry*, 2010 Nov; 16(10): 903-912.
- Etiminan M, **Samii A**, Brophy JM. Statin use and risk of epilepsy. *Neurology*, 2010 Oct; 75(17): 1496-1500.
- Gabel MJ, Foster NL, Heidebrink JL, Higdon R, Aizenstein HJ, Arnold SE, Barbas NR, Boeve BF, Clark CM, Dekosky ST, Farlow MR, Jaquist WJ, Kawas CH, Koeppe RA, **Leverenz JB**, Lipton AM, Peskind ER, Turner RS, Womack KB, Zamrini EY. Validation of consensus panel diagnosis in dementia. *Arch Neurol.*, 2010 Dec; 67(12): 1506-1512.
- Hamza TH, **Zabetian CP**, Tenesa A, Laederach A, Montimurro, Yearout D, Kay DM, Doheny KF, Paschall J, Pugh E, Kusel VI, Collura R, Roberts J, Griffith A, **Samii A**, Scott WK, **Nutt J**, Factor SA, Payami H. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. *Nature Genetics*, 2010 Jul; 42: 781-785.
- Hong, Z, Shi M, **Chung KA, Quinn JF**, Peskind ER, Galasko D, Jankovic J, **Zabetian CP, Leverenz JB**, Baird G, Montine TJ, Hancock AM, Hwang H, Pan C, Bradner J, Kang UJ, Jensen PH and Zhang J. DJ-1

- and α -synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. *Brain*, 2010, 133(3): 713-726.
- Hwang H, Zhang J, **Chung KA**, **Leverenz JB**, **Zabetian CP**, Peskind ER, Jankovic J, Su Z, Hancock AM, Pan C, Montine TJ, Pan S, **Nutt J**, Albin R, Gearing M, Beyer RP, Shi M, Zhang J. Glycoproteomics in neurodegenerative diseases. *Mass Spectrom Rev*. 2010 Jan-Feb;29(1):79-125.
- Jun G, Naj AC, Beecham GW, Wang LS, Buross J, Gallins PJ, Buxbaum JD, Ertekin-Taner N, Fallin MD, Friedland R, Inzelberg R, Kramer P, Rogaeva E, St George-Hyslop P, Cantwell LB, Dombroski BA, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Lunetta KL, Martin ER, Montine TJ, Goate AM, Blacker D, Tsuang DW, Beekly D, Cupples LA, Hakonarson H, Kukull W, Foroud TM, Haines J, Mayeux R, Farrer LA, Pericak-Vance MA, Schellenberg GD; Alzheimer's Disease Genetics Consortium, Arnold SE, Baldwin CT, Barber R, Beach T, Bigio EH, Bird TD, Boxer A, Burke JR, Cairns N, Carroll SL, Chui HC, Clark DG, Cotman CW, Cummings JL, Decarli C, Diaz-Arrastia R, Dick M, Dickson DW, Ellis WG, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Gearing M, Geschwind DH, Ghetti B, Gilman S, Giordani B, Glass J, Graff-Radford NR, Green RC, Growdon JH, Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jicha GA, Jin LW, Johnson N, Karlawish J, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Lah JJ, Levey AI, Lieberman A, Lopez OL, Mack WJ, Markesbery W, Marson DC, Martiniuk F, Masliah E, McKee AC, Mesulam M, Miller JW, Miller BL, Miller CA, Parisi JE, Perl DP, Peskind E, Petersen RC, Poon W, **Quinn JF**, Raskind M, Reisberg B, Ringman JM, Roberson ED, Rosenberg RN, Sano M, Schneider JA, Schneider LS, Seeley W, Shelanski ML, Smith CD, Spina S, Stern RA, Tanzi RE, Trojanowski JQ, Troncoso JC, Van Deerlin VM, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Woltjer RL, Younkin SG. Meta-analysis Confirms CR1, CLU, and PICALM as Alzheimer Disease Risk Loci and Reveals Interactions With APOE Genotypes. *Arch Neurol*. 2010 Dec;67(12):1473-84.
- Kay DM, Stevens CF, Hamza TH, Montimurro JS, **Zabetian CP**, Factor SA, **Samii A**, Griffith A, Roberts JW, Molho ES, Higgins DS, Gancher S, Moses L, Zareparsis S, Poorkaj P, Bird T, Nutt J, Schellenberg GD, Payami H. A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2. *Journal of Neurology*, 2010 Sep; 75(13): 1189-1194.
- King LA, St George RJ, Carlson-Khuta P, **Nutt JG**, Horak FB. Preparation for compensatory forward stepping Parkinson's disease. *Arch Phys Med Rehabil*, 2010 Sep; 91(9): 1332-1338.
- Margiotta N, Denora N, Ostuni R, Laguintana V, Anderson A, **Johnson SW**, Trapani G, Natile G. Platinum(II) complexes with bioactive carrier ligands having high affinity for the translocator protein. *Journal of Medical Chemistry*, 2010 July; 53(14): 5144-5154.
- Marks WJ Jr, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, Vitek J, Stacy M, Turner D, Verhagen L, Bakay R, Watts R, Guthrie B, Jankovic J, Simpson R, Tagliati M, Alterman R, Stern M, Baltuch G, Starr PA, Larson PS, Ostrem JL, **Nutt J**, Kiebertz K, Kordower JH, Olanow CW. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. *Lancet Neurol*. 2010 Dec;9(12):1164-72.
- Mata IF, Shi M, Agarwal P, **Chung KA**, Edwards KL, Factor SA, Galasko DR, Ghingina C, Griffith A, Higgings DS, Kay DM, Kim H, **Leverenz JB**, **Quinn JF**, Roberts JW, **Samii A**, Snapinn KW, Tsuang DW, Yearout D, Zhang J, Payami H, **Zabetian CP**. A SNCA variant associated with Parkinson's disease and plasma α -synuclein level. *Arch Neurol*. 2010 Nov;67(11):1350-6.

- McMillan PJ, **Leverenz JB**. From model system to clinical medicine: pathophysiologic links of common proteinopathies. *Alzheimers Res Ther*. 2010 Sep 16;2(5):26.
- Montine TJ, Shi M, **Quinn JF**, Peskind ER, Craft S, Ghingina C, **Chung KA**, Kim H, Galasko DR, Jankovic J, **Zabetian CP**, **Leverenz JB**, Zhang J. CSF Abeta(42) and tau in Parkinson's disease with cognitive impairment. *Mov Disord*. 2010 Nov 15;25(15):37-43.
- Nutt JG**, **Chung KA**, Holford NH. Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study. *Neurology*. 2010 Apr 13;74(15):1191-7.
- Okun MS, Siderowf A, **Nutt JG**, O'Connor GT, Bloem BR, Olmstead EM, Guttman M, Simuni T, Cheng E, Cohen EV, Parashos S, Marsh L, Malatay IA, Giladi N, Schmidt P, Oberdorf J. Piloting the NPF data-driven quality improvement initiative. *Parkinsonism Related Disorders*, 2010 Sep; 16(8): 517-521.
- Paquette MA, Anderson AM, Lewis JR, Meshul CK, **Johnson SW**, and Berger SP. MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism. *Neuropharmacology*, 2010 Jun; 58(7): 1002-1008.
- Peterson A**. Patient management problem. *Continuum Lifelong Learning Neurol* 2010;16(1).
- Piacentini J, Woods DW, Scahill L, Willhelm S, **Peterson AL**, Chang S, Ginsburg GS, Deckersbach T, Dziura J, Levi-Pearl S, Walkup JT. Behavior therapy for children with Tourette disorder: a randomized controlled trial. *JAMA*, 2010 May; 303(19): 1929-1937.
- Poorkaj P, Raskind WH, **Leverenz JB**, Matsushita M, **Zabetian CP**, **Samii A**, Kim S, Gazi N, **Nutt JG**, Wolff J, Yearout D, Greenup JL, Steinbart EJ, Bird TD. A novel X-linked four-repeat tauopathy with Parkinsonism and spasticity. *Movement Disorder Society*, 2010 July; 25(10): 1409-1417.
- Quinn JF**, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, Galvin JE, Emond J, Jack CR Jr, Weiner M, Shinto L, Aisen PS. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. *JAMA*, 2010 Nov; 304(17): 1903-1911.
- Quinn JF**, Harris CJ, Cobb KE, Domes C, Ralle M, Brewer G, Wadsworth TL. A Copper-Lowering Strategy Attenuates Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease. *J Alzheimers Dis*. 2010;21(3):903-14.
- Quinn JF**, Harris CJ, Cobb KE, Domes C, Ralle M, Brewer G, Wadsowrth TL. A copper-lowering strategy attenuates amyloid pathology in a transgenic mouse model of Alzheimer's disease. *Journal of Alzheimers Disease*, 2010; 21(3): 903-914.
- Safavi-Abbasi S, González-Felipe V, Gharabaghi A, Talley MC, Bambakidis NC, Preul MC, Samii M, **Samii A**, Freund HJ. A functional magnetic resonance imaging study of factors influencing motor function after surgery for gliomas in the rolandic region. *World Neurosurg*. 2010 May;73(5):529-40.
- Shen KZ, **Johnson SW**. Ca²⁺ Influx through NMDA-gated channels activates ATP-sensitive K⁺ currents through a nitric oxide-cGMP pathway in subthalamic neurons. *The Journal of Neuroscience*, 2010 Feb; 30(5): 1882-1893.

- Shi M, **Zabetian CP**, Hancock AM, Gingham C, Hong Z, Yearout D, **Chung KA**, **Quinn JF**, Peskind ER, Galasko D, Jankovic J, **Leverenz JB**, Zhang J. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. *Neurosci Lett*. 2010 Aug 9;480(1):78-82.
- Sonnen JA, Montine KS, **Quinn JF**, Breitner JC, Montine TJ. Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment and Dementia. *J Alzheimers Dis*. 2010. 19(1):301-9.
- St George RJ, **Nutt JG**, Burchiel KJ, Horack FB. A meta-regression of the long-term effects of deep brain stimulation on balance and gait in PD. *Neurology*, 2010 Oct; 75(14):1292-1299.
- Stieglitz LH, Giordano M, Gerganov V, Raabe A, **Samii A**, Samii M, Ludemann WO. Petrous bone pneumatization is a risk factor for cerebrospinal fluid fistula following vestibular schwannoma surgery. *Neurosurgery*, 2010 Dec; 67(2): 509-515
- Subramanian S, Ayala P, Wadsworth TL, Harris CJ, Vandenberg AA, **Quinn JF**, Offner H. CCR6: A Biomarker for Alzheimer's-like Disease in a Triple Transgenic Mouse Model. *J Alzheimers Dis*. 2010 ; 22(2):619-29.
- Timmerman L, Pauls KA, Wieland K, Jech R, Kurlemann G, Sharma N, Gill SS, Haenggeli CA, Hayflick SJ, **Hogarth P**, Leenders KL, Limousin P, Malanga CJ, Moro E, Ostrem JL, Santens P, Schnitzler A, Tisch S, Valldeoriola F, Vesper J, Volkmann J, Woitalla D, Peker S. Dystonia in neurodegeneration with brain iron accumulation: outcome of bilateral pallidal stimulation. *Brain*, 2010 Mar; 133(3): 701-712.
- Woltjer RL, Duerson K, Fullmer JM, Mookherjee P, Ryan Am, Montine TJ, Kaye JA, **Quinn JF**, Silbert L, Erten-Lyons D, Leverenz JB, Bird TD, Pow DV, Tanaka K, Watson GS, Cook DG. Aberrant detergent-insoluble excitatory amino acid transporter 2 accumulates in Alzheimer disease. *Journal of Neuropathol. Exp. Neurol*, 2010 Jul; 69(7): 667-676.
- Wright WG, Gurfinkel VS, King LA, **Nutt JG**, Cordo PJ, Horak FB. Axial kinesthesia is impaired in Parkinson's disease: effects of levodopa. *Exp Neurol*. 2010 Sep; 225(1):202-209.